发明名称 New N-benzyl-anthranilic acid (hetero)arylamide derivatives and analogs, are tyrosine kinase KDR and FLT inhibitors and angiogenesis inhibitors, useful e.g. for treating tumors, psoriasis or restenosis
摘要 N-(Hetero)aryl-2-(N-(aminobenzyl)-amino)-benzamide and 2-amino-nicotinamide derivatives (I), including their enantiomers, diastereomers, tautomers and salts, are new. N-(Hetero)aryl-2-(N-(aminobenzyl)-amino)-benzamide and 2-amino-nicotinamide derivatives of formula (I), including their enantiomers, diastereomers, tautomers and salts, are new. X = CH or N; W = H or F; A1-A5 = CH or N, provided that not more than two are N; R1 = aryl or heteroaryl (both optionally substituted (os) by one or more of halo, OH, T, 3-6C cycloalkyl, 3-6C alkenyl, 2-6C alkynyl, aralkoxy, OT, haloalkyl, cyanoalkyl, =O, OR5 or SO2R6, where 1-6C alkyl groups are os by OR5 or NR9R10); T = 1-12C alkyl; Y, Y' = a bond, CO, CS or SO2; R2, R3 = H, CONR9R10, SO2R6, COR11, CO-alkyl, CO-alkyl-R11 or NR9R10, or alkyl, 3-10C cycloalkyl, 3-6C cycloalkenyl, aryl or heteroaryl (all os by one or more of halo, CN, T, OT, hydroxyalkyl, haloalkyl, NR7R8, OR5, alkyl-OR6, SR4, SOR4 or SO2R6); or N(YR2)Y'R3 = 3-8 membered (un)saturated ring, optionally containing further heteroatoms and os by one or more of halo, T, OT', haloalkyl, hydroxyalkyl, =O, OR5, SR4, SOR4 or SO2R6; T' = T or 1-12C haloalkyl; R4 = T, aryl or heteroaryl; R5 = H, T', 3-10C cycloalkyl or 3-6C halocycloalkyl; R6 = H, T' or NR9R10, or aryl or heteroaryl (both os by one or more of T, alkoxy, halo or haloalkoxy); R7, R8 = H or T; R9, R10 = H, alkyl, 2-6C alkenyl, aryl, 3-8C cycloalkyl or CONR7R8, or T (os by one or more of aryl (os by one or more of alkoxy or haloalkyl), morpholino, OH, halo, OT or NR7R8); or NR9R10 = 5-8 membered ring, optionally containing additional heteroatoms; and R11 = alkyl, alkoxy, hydroxyalkyl, hydroxyalkoxy, 3-6C cycloalkyl or phenyl (os by one or more of alkyl or haloalkyl), pyridyl, biphenylyl or naphthyl. Alkyl moieties have 1-6C unless specified otherwise. An Independent claim is also included for anthranilic and aminonicotinic acid derivatives of formulae (II) and (III) as intermediates in the preparation of (I). M = halo; Q = a leaving group (e.g. halo, O-triflate, O-mesylate, O-tosylate or sulfone) or N(YR2)Y'R3; and Ry = H or 1-6C alkyl.
申请公布号 DE10235690(A1) 申请公布日期 2004.02.19
申请号 DE20021035690 申请日期 2002.07.31
申请人 SCHERING AG 发明人 HUTH, ANDREAS;KRUEGER, MARTIN;ZORN, LUDWIG;STUART, INCE;THIERAUCH, KARL-HEINZ;MENRAD, ANDREAS;HABEREY, MARTIN;HESS-STUMPP, HOLGER
分类号 C07D213/61;C07D213/73;C07D213/74;C07D213/75;C07D401/04;C07D401/12;C07D401/14;C07D409/12;C07D413/04;C07D413/14;C07D417/04;(IPC1-7):C07D213/74;A61K31/44 主分类号 C07D213/61
代理机构 代理人
主权项
地址